The authors of this study showed that the CIS-deficient NK cells had improved metabolic fitness, caused by upregulated mTOR activity, suggesting that the mTOR inhibitors that are currently being trialed for various cancers may inadvertently dampen NK cell metabolic activity and therefore function. Here, MTOR is linked to in situ carcinoma.